Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02394340 · ClinicalTrials.gov registry record · Phase 4
Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris
A Phase 4 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT02394340 is a Phase 4 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 20 participants.
The verdict
NCT02394340, a Phase 4 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is an open-label, maximal use study to evaluate whether luliconazole in plasma acts as an inhibitor of cytochrome P2C19 (CYP2C19) as measured by circulating levels of omeprazole before and after treatment with a maximum dose of luliconazole cream 1% in participants with moderate to severe tinea pedis and tinea cruris.
Interventions
- DRUG Omeprazole 40 mg
- DRUG Luliconazole Cream 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-02-03 |
| Est. Completion | 2015-04-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02394340
The ClinicalTrials.gov registry entry for NCT02394340 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Omeprazole 40 mg is the first listed.
NCT02394340 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02394340 about?
NCT02394340 is a clinical study titled "Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris". This is an open-label, maximal use study to evaluate whether luliconazole in plasma acts as an inhibitor of cytochrome P2C19 (CYP2C19) as measured by circulating levels of omeprazole before and after treatment with a maximum dose of luliconazole cream 1% in participants with moderate to severe tinea...
What is the current status of trial NCT02394340?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2015-02-03. Estimated completion is 2015-04-01.
What interventions are being tested in trial NCT02394340?
The interventions under investigation include: Omeprazole 40 mg (DRUG), Luliconazole Cream 1% (DRUG).
Who is sponsoring clinical trial NCT02394340?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.